Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a spot or growth in their lung that doctors are concerned may be cancerous — either a primary lung cancer or cancer that has spread to the lung from elsewhere — whether or not a biopsy has already confirmed it
- People who are already scheduled to have surgery to remove a lung nodule or mass, either to find out what it is or to treat it
- People who are reasonably active and able to carry out daily activities, as measured by standard medical scoring tools (confirm with trial site for exact thresholds)
- People whose blood haemoglobin level is 9 grams per decilitre or above, indicating they are not severely anaemic
- People whose white blood cell count is above a certain minimum level, showing the immune system is functioning adequately
- People whose platelet count — the cells that help blood clot — is at or above a certain minimum level
- People whose kidney function, as measured by a blood test called serum creatinine, is within an acceptable range
Who may not be able to join:
- People who have taken part in another clinical drug trial and received an experimental drug within the 30 days before the first dose of the study drug
- People who have had a heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable chest pain within the six months before enrolling
- People who have previously had a serious reaction to a type of medication called a monoclonal antibody, given through a drip or injection
- People who are pregnant or currently breastfeeding
- People whose magnesium or potassium blood levels are below the normal range used by the treating institution
- People who are taking certain heart rhythm medications, specifically class IA drugs (such as quinidine or procainamide) or class III drugs (such as dofetilide, amiodarone, or sotalol)
- People who have a history of, or signs of, inflammatory lung disease or scarring of the lungs (such as interstitial pneumonitis or pulmonary fibrosis)
- People who are prisoners, living in an institution, or are otherwise unable to give their own informed consent to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Natalie Lui, Stanford University
Phone: 650-721-2086
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Tumor to background ratio (TBR), measured in ex vivo tissues
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.